# AF Beyond the Lesion: Can We Stop Anticoagulation, Trust Sham Trials, and Treat AF as a Metabolic Disease?

Page: https://stenobird.com/podcast/ep-edge-journal-watch-7561379/af-beyond-the-lesion-can-we-stop-anticoagulation-trust-sham-trials-and-treat-af-as-a-metabolic-disease
Text version: https://stenobird.com/podcast/ep-edge-journal-watch-7561379/af-beyond-the-lesion-can-we-stop-anticoagulation-trust-sham-trials-and-treat-af-as-a-metabolic-disease.md
Podcast: [EP Edge Journal Watch](https://stenobird.com/podcast/ep-edge-journal-watch-7561379)
Published: 2025-12-18T10:30:00+00:00
Episode link: https://share.transistor.fm/s/0d109cba
Audio file: https://media.transistor.fm/0d109cba/1f9d93c8.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/af-beyond-the-lesion-can-we-stop-anticoagulation-trust-sham-trials-and-treat-af-as-a-metabolic-disease
Duration seconds: 943

## Resource

In this December 2025 episode of EP Edge Journal Watch , Dr. Niraj Sharma breaks down the most provocative atrial fibrillation trials of the year—studies that force us to rethink what really drives AF outcomes beyond the ablation lesion EP EDGE JW Dec 2025 Newsletter. We dive deep into four game-changing themes shaping modern electrophysiology: Can we safely stop anticoagulation after AF ablation? A critical analysis of OCEAN (NEJM 2025) and ALONE-AF , exploring DOAC de-escalation, aspirin as a comparator, and whether selected AF-free patients may safely discontinue oral anticoagulation. Is AF ablation real—or partly placebo? A deep dive into sham-controlled ablation trials , including SHAM-PVI and the landmark PFA-SHAM trial , providing definitive evidence that both thermal and pulsed-field ablation deliver true reductions in AF burden and meaningful quality-of-life benefits. Are metabolic drugs the next AF substrate therapy? We examine emerging data on GLP-1 receptor agonists (semaglutide) , metformin , and SGLT2 inhibitors after AF ablation—highlighting which therapies reduce recurrence and which fail when used purely as off-label antiarrhythmics. Why do women run faster sinus rates than men? A fascinating look at human sinoatrial node transcriptomics , explaining sex-specific heart-rate biology and its implications for inappropriate sinus tachycardia, sinus node dysfunction, and AF progression. What you’ll learn Why the “ DOAC for life ” paradigm after AF ablation is beginning to crack How sham trials finally settle the debate about ablation’s true efficacy Which metabolic drugs actually modify AF substrate—and which do not How sex-specific sinus node biology should influence EP decision-making This episode moves electrophysiology beyond lesion sets toward precisio…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/af-beyond-the-lesion-can-we-stop-anticoagulation-trust-sham-trials-and-treat-af-as-a-metabolic-disease/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/ep-edge-journal-watch-7561379/af-beyond-the-lesion-can-we-stop-anticoagulation-trust-sham-trials-and-treat-af-as-a-metabolic-disease.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.